CoLucid Pharmaceuticals, Inc.

Shareholder Corporation Litigation

Rigrodsky & Long, P.A. Announces Investigation Of CoLucid Pharmaceuticals, Inc. (NASDAQ GM: CLCD) Buyout

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of CoLucid Pharmaceuticals, Inc. (“CoLucid” or the “Company”) (NASDAQ GM: CLCD) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Eli Lilly and Company (“Eli Lilly”) (NYSE: LLY), in a transaction valued at approximately $960 million.

Under the terms of the agreement, shareholders of CoLucid will receive $46.50 in cash for each share of CoLucid common stock.

The investigation concerns whether CoLucid’s board of directors failed to adequately shop the Company and obtain the best possible value for CoLucid shareholders before entering into an agreement with Eli Lilly.

If you own the common stock of CoLucid and purchased your shares before January 18, 2017, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803, by telephone at (888) 969-4242; by e-mail to

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, on behalf of shareholders in states and federal courts throughout the United States.

Attorney advertising.  Prior results do not guarantee a similar outcome.